Nucleic acid microspheres, production and delivery thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-035/16
A01N-043/04
출원번호
UP-0127362
(2005-05-12)
등록번호
US-7815941
(2010-11-08)
발명자
/ 주소
Brown, Larry R.
Scott, Terrence L.
Lafreniere, Debra
Bisker-Leib, Vered
출원인 / 주소
Baxter Healthcare S.A.
Baxter International Inc.
대리인 / 주소
Marshall, Gerstein & Borun LLP
인용정보
피인용 횟수 :
0인용 특허 :
84
초록▼
Nucleic acids are prepared by dissolving compounds containg them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatm
Nucleic acids are prepared by dissolving compounds containg them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.
대표청구항▼
The invention claimed is: 1. An aqueous process for producing biologically active microspheres comprising nucleic acids, the process comprising (a) dissolving the nucleic acids with an aqueous solvent to form an aqueous composition, wherein at least one water soluble polymer is added to the aqueous
The invention claimed is: 1. An aqueous process for producing biologically active microspheres comprising nucleic acids, the process comprising (a) dissolving the nucleic acids with an aqueous solvent to form an aqueous composition, wherein at least one water soluble polymer is added to the aqueous solvent, and (b) forming microspheres comprising nucleic acids, said microspheres having an average particle size of not greater than about 50 microns and being substantially free of said polymer. 2. The process according to claim 1, wherein at least one polycation is added to said solvent. 3. The process according to claim 2, wherein said polycation is poly-lysine. 4. The process according to claim 3, wherein said polycation is poly-ornithine. 5. The process according to claim 1, wherein said nucleic acids are a first polyanion and wherein at least a second polyanion is added to said solvent. 6. The process according to claim 1, wherein said polymer is polyethylene glycol and polyvinyl pyrollidone. 7. The process according to claim 1, wherein said forming is carried out with the addition of a crosslinking agent to the composition. 8. The process according to claim 1, wherein said dissolving is carried out with the addition of energy to the composition. 9. An aqueous process for producing biologically active microspheres comprising nucleic acids, the process comprising dissolving the nucleic acids with an aqueous solvent to form a composition, wherein at least one water soluble polymer is added to the aqueous solvent, and forming nucleic acid microspheres from said composition, said microspheres having an average particle size of not greater than about 50 microns and substantially free of polymer, wherein said forming is carried out in the absence of a polycation component in said composition. 10. The process according to claim 1, wherein said forming is carried out in the absence of a cross-linking component in said composition. 11. The process according to claim 1, wherein said nucleic acids are a first polyanion and wherein said forming is carried out in the absence of a second polyanion component in said composition. 12. The process according to claim 1, wherein said forming is carried out in the absence of applying an energy source to form said microspheres from said composition. 13. The process according to claim 9 wherein said forming is carried out in the absence of a cross-linking component in said composition. 14. The process according to claim 9, wherein said nucleic acids are a first polyanion and said forming is carried out in the absence of a second polyanion component in said composition. 15. The process according to claim 9, wherein said forming is carried out in the absence of applying an energy source to form said microspheres from said composition. 16. The process according to claim 1, wherein the nucleic acids in the microspheres are less susceptible to nuclease degradation than the nucleic acids dissolved in the solvent. 17. The process according to claim 9, wherein the nucleic acids in the microspheres are less susceptible to nuclease degradation than the nucleic acids dissolved in the solvent. 18. The process of claim 1, wherein said dissolving in step (a) is carried out with the addition of heat and said forming in step (b) is carried out by cooling the composition. 19. The process according to claim 18, wherein said composition is cooled to from about 35° C. to about −196° C. 20. The process according to claim 18, wherein said composition remains a suspension as said cooling step is carried out. 21. The process according to claim 18, wherein the cooling is carried out at a rate of from about 0.1° C. to about 400° C. per minute. 22. The process according to claim 18, wherein the cooling provides a turbidity in the composition, wherein the turbidity comprises the microspheres. 23. The process according to claim 1 wherein, wherein said average particle size of the microspheres is between 0.04 and 10 microns. 24. The process according to claim 1 wherein, wherein said average particle size of the microspheres is between 0.04 and 5 microns. 25. The process according to claim 1, wherein said average particle size of the microspheres is between about 0.04 and about 8 microns. 26. The process according to claim 1, wherein said average particle size of the microspheres is between about 0.1 and about 4 microns. 27. The process according to claim 1, wherein said average particle size of the microspheres is between about 0.2 and about 4 microns. 28. The process according to claim 1, wherein said average particle size of the microspheres is between about 1 and about 3 microns. 29. The process according to claim 1, wherein nucleic acids comprise up to about 100 weight percent of the microspheres formed by the process. 30. The process according to claim 1, wherein nucleic acids comprise approximately 100 weight percent of the microspheres formed by the process. 31. The process according to claim 1, wherein nucleic acids comprise at least 20 weight percent of the microspheres formed by the process. 32. The process according to claim 1, wherein nucleic acids comprise at least 30 weight percent of the microspheres formed by the process. 33. The process according to claim 1, wherein nucleic acids comprise at least 50 weight percent of the microspheres formed by the process. 34. The process according to claim 1, wherein nucleic acids comprise at least 70 weight percent of the microspheres formed by the process. 35. The process according to claim 1, wherein nucleic acids comprise at least 90 weight percent of the microspheres formed by the process. 36. The process according to claim 1, wherein nucleic acids comprise at least 95 weight percent of the microspheres formed by the process. 37. The process according to claim 1, wherein nucleic acids comprise between about 30 and about 100 weight percent of the microspheres formed by the process. 38. The process of claim 1, wherein after said forming the microspheres are washed, yielding an aqueous suspension of microspheres. 39. The process according to claim 1, wherein after said forming the microspheres are washed and then dried to yield a dry powder. 40. The process according to claim 1, wherein the composition further comprises multiple biologically active agents, yielding microspheres comprised of multiple bioactive agents. 41. The process according to claim 1, wherein the composition further comprises a buffer. 42. The process according to claim 1, wherein the nucleic acids are thiolated. 43. The process according to claim 1, wherein the microspheres precipitate from an aqueous solution. 44. The process according to claim 1, wherein the microspheres are comprised of amorphous or semi-crystalline nucleic acids. 45. The process of claim 1, wherein step (a) is carried out at a temperature of from about 4° C. to about 100° C. 46. The process according to claim 2, wherein said polymer is polyethylene glycol and polyvinyl pyrollidone. 47. The process according to claim 2, wherein said forming is carried out with the addition of a crosslinking agent to the composition. 48. The process of claim 2, wherein said dissolving in step (a) is carried out with the addition of heat and said forming in step (b) is carried out by cooling the composition. 49. The process of claim 48, wherein step (b) comprises cooling the composition to a temperature of from about 35° C. to about −196° C. 50. The process of claim 2, wherein step (a) is carried out at a temperature of from about 4° C. to about 100° C. 51. The process according to claim 2, wherein step (a) comprises (i) adding at least one polycation and said nucleic acid to said solvent to form a solution, and (ii) adding water-soluble polymer to the solution of step (a). 52. The process of claim 51, wherein step (a) is carried out at a temperature of from about 4° C. to about 100° C. 53. The process according to claim 2 wherein, wherein said average particle size of the microspheres is between 0.04 and 10 microns. 54. The process according to claim 52 wherein, wherein said average particle size of the microspheres is between 0.04 and 5 microns. 55. The process according to claim 2, wherein said average particle size of the microspheres is between about 0.04 and about 8 microns. 56. The process according to claim 2, wherein said average particle size of the microspheres is between about 0.1 and about 4 microns. 57. The process according to claim 2, wherein said average particle size of the microspheres is between about 0.2 and about 4 microns. 58. The process according to claim 2, wherein said average particle size of the microspheres is between about 1 and about 3 microns. 59. The process according to claim 2, wherein nucleic acids comprise at least 20 weight percent of the microspheres formed by the process. 60. The process according to claim 2, wherein nucleic acids comprise at least 30 weight percent of the microspheres formed by the process. 61. The process according to claim 2, wherein nucleic acids comprise at least 50 weight percent of the microspheres formed by the process. 62. The process according to claim 2, wherein nucleic acids comprise at least 70 weight percent of the microspheres formed by the process. 63. The process according to claim 2, wherein nucleic acids comprise at least 90 weight percent of the microspheres formed by the process. 64. The process according to claim 2, wherein nucleic acids comprise a least 95 weight percent of the microspheres formed by the process. 65. The process according to claim 2, wherein nucleic acids comprise between about 30 and about 100 weight percent of the microspheres formed by the process. 66. The process of claim 2, wherein after said forming the microspheres are washed, yielding an aqueous suspension of microspheres. 67. The process according to claim 2, wherein after said forming the microspheres are washed and then dried to yield a dry powder. 68. The process according to claim 2, wherein the composition further comprises multiple biologically active agents, yielding microspheres comprised of multiple bioactive agents. 69. The process according to claim 2, wherein the composition further comprises a buffer. 70. The process according to claim 2, wherein the nucleic acids are thiolated. 71. The process according to claim 2, wherein the microspheres precipitate from an aqueous solution. 72. The process according to claim 2, wherein the microspheres are comprised of amorphous or semi-crystalline nucleic acids. 73. The process according to claim 2, wherein the volumetric ratio of polycation:nucleic acid in the composition is from about 0.5:1 to about 4:1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (84)
Bennett C. Frank ; Cowsert Lex M., Antisense modulation of CD40 expression.
Hubbell Jeffrey A.,CHX ; Kieras Mark T. ; Ron Eyal S. ; Rowe Stephen C., Biodegradable macromers for the controlled release of biologically active substances.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Singh Maninder (Mountain Brook Rodeo CA) Nunberg Jack H. (Mountain Brook Oakland CA) Tice Thomas R. (Mountain Brook Birmingham AL) Hudson Michael E. (Mountain Brook Gardendale AL) Gilley Richard M. (, Controlled-release formulations of interleukin-2.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Cohen Smadar (Petach-Tickva ILX) Bano Carmen (Valencia PA ESX) Visscher Karyn B. (State College PA) Chow Marie (Brookline MA) Allcock Harry R. (State College PA) Langer Robert S. (Newton MA), Ionically cross-linked polymeric microcapsules.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Tice Thomas R. (Birmingham AL) Dillon Deborah L. (Helena AL) Mason David W. (Birmingham AL) McRae-McFarlane Amanda (Vastra Frolunda SEX) Dahlstrom Annica B. (Askin SEX), Method for stimulating nerve fiber growth.
Jones David Hugh,GBX ; Farrar Graham Henry,GBX ; Clegg James Christopher Stephen,GBX, Method of making microencapsulated DNA for vaccination and gene therapy.
Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Eldridge John H. (Birmingham AL) Staas Jay K. (Birmingham AL) Hollingshead Melinda G. (Birmingham AL) Shannon William M. (Birmingham A, Method of potentiating an immune response.
Bot, Adrian I.; Tarara, Thomas E.; Weers, Jeffry G.; Kabalnov, Alexev; Schutt, Ernest G.; Dellamary, Luis A., Particulate delivery systems and methods of use.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Ramstack J. Michael (Lebanon OH) Herbert Paul F. (Wayland MA) Strobel Jan (Westchester OH) Atkins Thomas J. (Cincinnati OH), Preparation of biodegradable microparticles containing a biologically active agent.
Cha Younsik (Salt Lake City UT) Choi Young Kweon (Salt Lake City UT) Pai Chaul Min (Taejon KRX), Preparation of peptide containing biodegradable microspheres by melt process.
Bruno, Maria; Tagliaferri, Jenna; Lawson, Luke; Logan, Mark J.; Mumper, Russ, Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods.
Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
Park, Jin Kyu; Park, Mork Soon; Kim, Dong Seon; Lim, Il Ho; Jee, Ung Kil; Myung, Pyung Keun; Kim, San Beom; Jung, Goo Young, Sustained release microparticle and method for preparing the same.
Reid Robert H. (Kensington MD) Boedeker Edgar C. (Chevy Chase MD) van Hamont John E. (Shape MD BEX) Setterstrom Jean A. (Takoma Park MD), Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompa.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.